First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Investment case

    Replimune Group, Inc.

    REPL · 2 developments mapped · last assessed 2026-08-14

    Market Ontology has mapped 2 macro, policy, and market developments to Replimune Group, Inc. since 2026-08-14. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.

    Last close
    Unavailable
    No published quote
    Market cap
    Unavailable
    Equity value
    Diluted shares
    Unavailable
    Latest reported
    Sector
    Unavailable
    Listing
    Unavailable
    Filings
    Unavailable
    No published filing

    Valuation

    No validated run has been published for REPL yet, so no modelled value is shown. The REPL valuation is in the public catch-up queue.

    Subscribers do not wait for the weekly cycle: they run REPL on demand, against live prices and the latest filings, and change any assumption the developments below move.

    Filed financials

    A validated filed-statement snapshot has not been published for REPL. Missing data is not estimated or replaced with scenario assumptions.

    Current case

    • Strongest support

      Replimune Group, Inc. Follow-On — $150M

      Enhanced financial stability and ability to execute strategic growth initiatives.

      · Moves time to market for tudriqev, peak sales potential of tudriqev, risk of clinical trial failure

    • Open question

      Replimune Group, Inc. Follow-On — $150M

      Direct equity dilution and increased cash reserves for operational funding.

      · Moves future cash burn rate, probability of successful commercialization, discount rate (due to reduced financing risk)

    What changed, by assumption

    Future cash burn rate
    • 2026-08-14Replimune Group, Inc. Follow-On — $150M
    Time to market for tudriqev
    • 2026-08-14Replimune Group, Inc. Follow-On — $150M

    Assumption changes

    Full ledger →
    DateAssumptionDirectionWhyConf.
    2026-08-10Valuation multipleBearishIncremental float typically compresses near-term multiple absent revenue acceleration.0.70
    2026-08-10Share countBullishPrimary equity issuance increases diluted share count.0.70
    2026-06-29Net debtBullishCash balance decreased from $483.8M to $268.9M year-over-year due to operating burn.0.90
    2026-06-29RevenueBullishFDA goal date of August 2, 2026 for RP1 BLA resubmission could lead to first commercial revenue.0.80
    2026-06-29Net debtBullishCash and short-term investments decreased from $483.8M to $268.9M year-over-year due to high operating burn.0.90

    Event impact log

    Full ledger →
    DateMechanismDirectionHorizonImpact
    2026-08-14Replimune Group, Inc. Follow-On — $150MBullish3-12m0.60
    2026-08-14Replimune Group, Inc. Follow-On — $150Mmixed1-3m0.70